Concerned about your own or
someone else’s drug use?


To build scope & capacity
for clinical research

NCCRED Symposium

Save the Date: NCCRED Symposium 7th November 2021 Brisbane Queensland

Save the Date: 7th November 2021

The 2021 NCCRED Symposium will be held on Sunday 7th November 2021. This will be in collaboration with The Australasian Professional Society on Alcohol & other Drugs (APSAD) Symposium. Stay tuned for more information

Innovations in therapeutic practice

NCCRED’s second national symposium on November 20, was a vital opportunity for the AoD sector to advance its collective response to emerging drugs.

The symposium focused on innovations in the therapeutic practice for methamphetamine disorder.

The symposium brought together leading national researchers, including presentations from recipients of NCCRED’s Round 2 Seed Funding Program, NCCRED Clinical Research Fellows, and NCCRED research team members, all sharing the most up-to-date aspects of their work and research around emerging drug use.

Areas of exploration in the 2020 symposium included:

  • New directions in pharmacotherapy for methamphetamine withdrawal
  • Networks and referral pathways for people with methamphetamine dependence
  • Emerging national drug monitoring networks

Check out our full program below or catch up with all presentation recordings. Slides coming soon.

We look forward to seeing you in 2021.

2020 Symposium Program

Download PDF

Session 1 – Methamphetamine use disorder: pharmacotherapies

Session 1 Presenters:

David Goodman

Assistant Professor, Division of Infectious Diseases, David Geffen School of Medicine at University of California, Los Angeles, USA

CTN-0110 (MURB): A Randomized, placebo-controlled trial of monthly injectable buprenorphine for methamphetamine use disorder with occurring opioid use. Skip to:

6min 20sec

Edward Mullen

NCCRED Research Fellow,

Consultant Psychiatrist, Hype and Substance Use Research Group and Early Intervention Clinic

An Open-Label Pilot Study of Subanaesthetic Ketamine for Stimulant Use Disorder – Methamphetamine Type in Youth Skip to:

25min 20sec

Liam Acheson

PhD Candidate, National Drug and Alcohol Research Centre (NDARC), University of New South Wales,

Research Officer, Alcohol and Drug Service, St Vincent’s Health Sydney

Lisdexamfetamine for the management of acute methamphetamine withdrawal: Protocol for an open-label safety and feasibility study Skip to:


Robert Ali

Chair, NCCRED Methamphetamine and Emerging Drugs Clinical Research Network Working Group,

Clinical Associate Professor in the Discipline of Pharmacology at the University of Adelaide

Discussant Skip to:

51min 20 sec

Session 2 – Methamphetamine use disorder: psychosocial interventions

Session 2 Presenters:

Alison Beck

Trial Coordinator, Clinical Psychologist, School of Psychology, University of Wollongong

Methamphetamine and mutual support: A mixed methods exploration of SMART Recovery participants’ characteristics and opportunities for enhanced referral pathways Skip to:

2min 30 sec

Victoria Manning 

Head of Research and Workforce Development, Turning Point, Eastern Health,

Associate Professor of Addiction Studies, Monash University

The methamphetamine approach-avoidance training (MAAT) trial: A randomised controlled trial of personalised approach bias modification for methamphetamine use  Skip to: 

12 min 50 sec

Adam Rubenis 

NCCRED Research Fellow,

Psychologist, Statewide Clinical Services, Turning Point (Eastern Health)

Collaborative development of a clinician-administered checklist to facilitate retention and therapeutic engagement in substance use treatment Skip to: 

25 min 45 sec

Rachel Reilly

Senior Research Fellow, Novel Interventions to Address Methamphetamine Use in Aboriginal and Torres Strait Islander Communities (NIMAC), Infection and Immunity Aboriginal Health, South Australian Health and Medical Research Institute (SAHMRI)

An acceptability and feasibility study of the We Can Do This online therapeutic program in primary care and residential rehabilitation settings Skip to:

34 min 40 sec

Annalee Stearne

Chair, NCCRED Aboriginal and Torres Strait Islander Working Group, & NCCRED Board member 

Research Associate/ PhD Candidate, National Drug Research Institute

Discussant  Skip to:

45 min 55 sec

Session 3 – Methamphetamine use disorder: using data for improved outcomes

Session 3 Presenters:

Emma Black

Senior Project Officer, Drug and Alcohol Services, South Eastern Sydney Local Health District, The Langton Centre

Developing a clinical data laboratory for methamphetamine use in NSW: The MAData project Skip to:

1 min 25 sec

Llewellyn Mills

Honorary Research Fellow, Central Clinical School, Faculty of Medicine
The University of Sydney & South Eastern Sydney Local Health District, The Langton Centre

Impact of Amphetamine Type Stimulant Use on Clinical Outcomes in OTP Clients Skip to:

12 min 30 sec

Krista Siefried

Deputy Director & Clinical Research Lead, National Centre for Clinical Research on Emerging Drugs (NCCRED)

Clinical outcomes and measures used in randomised controlled trials examining pharmacotherapy for methamphetamine dependence Skip to:

28 min 05 sec

Robert Stirling

NCCRED Board member

Chief Executive Officer, Network of Alcohol and Other Drugs Agencies

Discussant Skip to:

39 min 05 sec

Session 4 – Emerging drugs of concern: signal detection for prompt response

Session 4 Presenters:

Peter Stockham

Principal Forensic Scientist, Toxicology, Forensic Science SA

Conclusion of the South Australian Drug Early Warning System – Emergency Department Admission Blood Psychoactive Testing (EDABPT) Study Skip to:

1 min 15 sec

Jennifer Smith

Research Project Officer, Centre for Clinical Research in Emergency Medicine, Royal Perth Hospital

“Brevity of data will take precedence”: evolution of a national minimum dataset of illicit and emerging drugs in the emergency department Skip to:

10 min 10 sec

Andrew Kozman

NCCRED Research Fellow,

Emergency Consultant, Fiona Stanley Hospital

The implementation of the Recreational Drug Intoxication Protocol  Skip to:

22 min 50 sec

Rachel Sutherland

Research Fellow, National Drug and Alcohol Research Centre, University of New South Wales

Feasibility, consumer acceptability and behavioural outcomes associated with take-home fentanyl test strips Skip to:

32 min 05 sec

Jack Nagle

Founder of Realdrugtalk,

Member NCCRED Methamphetamine and Emerging Drugs Clinical Research Network Working Group

Discussant Skip to:

41 min 35 sec

Collaborate, Generate, Translate: Research meets clinical practice in methamphetamine and emerging drugs

In line with NCCRED’s aims, the symposium was designed to:

  • Collaborate to build research networks and capacity
  • Generate evidence-based knowledge
  • Translate research into best clinical practice

We gathered vastly experienced clinicians and researchers from some of the major drug and alcohol centres around the country. The program included presentations from Round 1 NCCRED Clinical Research Seed Funding Grant recipients, NCCRED Clinical Research Capacity Building Grant recipients, the NCCRED team and affiliates. They shared the most up-to-date aspects of their work and research around emerging drug use, including:

  • Drug monitoring and response networks around Australia
  • Treatment outcomes and methods
  • Future research priorities

Check out the program:


2019 Presentations

  1. Dr Krista Siefried, Clinical Research Lead, National Centre for Clinical Research on Emerging Drugs (NCCRED): A rapid clinical research priority assessment for substance use disorders due to methamphetamine and emerging drugs of concern in Australia
  2. Dr Emma Partridge, Forensic Scientist, Forensic Science SA: Results of the South Australian Drug Early Warning System – Emergency Department Admission Blood Psychoactive Testing (EDABPT) Study
  3. Dr Chris Tremonti, Advanced Trainee in Addiction and Pharmacology, Royal Prince Alfred Hospital: A randomised double-blind placebo-controlled study of Lisdexamfetamine for the treatment of methamphetamine dependence (LiMA) – RPAH experience of participant recruitment and retention
  4. Emma Black, Senior Project Officer, Drug and Alcohol Services, The Langton Centre: Characteristics and treatment outcomes of the drug treatment population in New South Wales – focus on amphetamine type stimulants (ATS)
  5. Dr Sandra Mitchell, Prompt Response Research Fellow, National Centre for Clinical Research on Emerging Drugs (NCCRED): Towards a prompt response network for Australia: rapid health communication about events related to emerging drugs of concern
  6. Roger Nicholas, Senior Researcher, National Centre for Education and Training on Addiction, Flinders University: The National Centre for Clinical Research on Emerging Drugs: Clinical Research Workforce Development Strategy
  7. Dr Craig Rodgers, Senior staff specialist, Alcohol and Drug Service, St Vincent’s Hospital Sydney: Sentinel surveillance for emerging illicitly manufactured fentanyl use in an inner-city opioid agonist treatment service
  8. Dr Briony Larance, Senior Research Fellow, University of Wollongong & Sarah Adams, Clinical Psychologist, Illawarra Drug and Alcohol Services: Drawing on regional data analytics and stakeholder consultation to improve responses to methamphetamine-related harm in a New South Wales Local Health District
  9. Dr Jessamine Soderstrom, Clinical Toxicologist, Emergency Physician, Royal Perth Hospital: Emerging Drug Network of Australia
  10. Liam Acheson, Research Officer, St Vincent’s Hospital Sydney: Optimising Care for People Who Inject Drugs: A retrospective medical record review of staphylococcus aureus bacteraemia treatment